Under one in 10 individuals that would benefit from obesity jabs such as Wegovy can access them, warns the World Health Organization as it releases its initial recommendations on the medications.
With in excess of 1,000,000,000 individuals worldwide now obese, it is advocating for broader and more equitable availability to this class of drugs.
Per forecasts, more than two billion are projected to be obese by 2030 without intervention.
"The new guidance recognises that excess weight is a long-term condition that can be managed with thorough and ongoing support," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and supply-chain constraints are key barriers to broad availability to the jabs that can assist patients in reducing significant weight, explains the organization.
Weight-Loss Drug Supply Crisis
Even under the current most optimistic scenario, the supply of such drugs might only reach around 100 million people – fewer than 10% of the global need, per the WHO.
The advice urges governments and firms to increase access, by measures like patent sharing.
Exclusive production rights on semaglutide – the core ingredient of a leading brand – is scheduled to end in several countries in 2026.
How Weight-Loss Injections Operate
These medications mimick a body's own hormone to delay gastric emptying, suppress the appetite and boost satiety so users consume fewer calories.
Patients commonly start to lose weight after several weeks of beginning the regular doses.
Studies suggests patients may regain a significant portion a year later of stopping the treatment, because their usual hunger come back.
To be overweight or obese increases your risk for experiencing diseases, such as diabetes, cardiovascular issues, stroke, and specific cancers.
Excess weight impacts people in all nations and was responsible for millions of fatalities worldwide in 2024, per the health agency.
